Article Text

Download PDFPDF
973 Immune-related protein changes due to standard of care therapy in recurrent ovarian cancer patients
  1. Julie Kempeneers1,2,
  2. Jolien Ceusters1,
  3. Gitte Thirion1,
  4. Sandra Claes3,
  5. Dominique Schols3,
  6. Thaïs Baert2 and
  7. An Coosemans1
  1. 1Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
  2. 2Department of Gynaecology and Obstetrics, Leuven Cancer Institute, UZ Leuven, Leuven, Belgium
  3. 3Department of Microbiology, Laboratory of Virology and Chemotherapy (Rega Institute), Immunology and Transplantation, KU Leuven, Leuven, Belgium


Introduction/Background High-grade serous ovarian cancer has a recurrence and mortality rate of approximately 80%. The impact of disease recurrence on the immune system remains unclear. Understanding this could potentially enhance our future therapeutic strategies.

Methodology We monitored 27 recurrent ovarian cancer patients treated with second-line chemotherapy (carboplatin-gemcitabine) and/or PARP(Poly(ADP-ribose)polymerase)-inhibition (PARPi) (OV-IMM-2014, S56311, University Hospitals Leuven). PARPi was administered as therapy (CLIO/BGOG-OV10) or in maintenance setting. Serum samples were taken at diagnosis of recurrence and after three or six cycles of treatment. Via Luminex technology, 17 immune-related proteins were assessed in nine sample pairs in the carboplatin-gemcitabine group and in 13 pairs in the PARPi group. The protein concentrations were compared during the treatment course and correlated with clinical parameters.

Results After six cycles of carboplatin-gemcitabine, CXCL-10 and CCL-5 increased, while CCL-2 and VEGF-A decreased in responding patients. In comparison, PARPi increased CXCL-10 and decreased CCL-2, VEGF-A, MMP-7 and CCL-5. Surprisingly, there was no difference in protein concentration or trends between patients who underwent secondary debulking surgery (SDS) or not, prior to carboplatin-gemcitabine. On the other hand, patients who underwent SDS prior to PARPi exhibited different trends in protein concentrations (galectin-3, MMP-7, TGF-β and CCL-5), compared to patients who did not undergo surgery. There was no difference in protein levels nor trends in patients who received PARPi in platinum-resistant versus platinum-sensitive setting.

Conclusion This study is among the first to highlight the immune changes during recurrence. Although populations were small, differences in the tumour immune micro-environment between patient groups were noticeable. Notably, tumour burden influenced the protein levels during PARPi treatment and chemotherapy response decreased immunosuppression. These findings could pave the way for future optimal immunotherapy planning.

Disclosures Non declared.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.